Patient Information
The Patient-Centered Dosing Initiative (PCDI) is based upon the principle that Metastatic Breast Cancer (MBC) drug dosages should be personalized for each patient based upon a standard set of criteria (below) to be discussed between the patient and their doctor.
MBC treatments, with the exception of endocrine therapy, are generally provided in a range of dosages. When starting a treatment, patients are usually placed on the standard (highest) dose - which can cause the most side effects.
Once a patient experiences significant side effects, their doctor may reduce the dose or frequency of the treatment to ease the patient's side effects. Although additional data is warranted, recent evidence regarding several MBC drugs has shown that prescribing approved reduced drug doses may not decrease effectiveness.
By discussing the criteria below before starting a treatment, you and your doctor may select an approved dose that is right for your situation and your individual preferences.
CRITERIA:
Your own personal goals and wishes
Your performance status (co-morbidities/medications, mobility and agility, current & past health situation, age, etc.)
Your history of side effects from prior drugs
Your current & historical blood count levels
Whether your disease is aggressive or indolent
Whether you have visceral crisis (severe organ dysfunction) or Central Nervous System (CNS) metastases
Your Body Mass Index (BMI)
Your personal financial situation (if additional medications are needed for side effect mitigation, can you afford them?)
Availability of in-home care (if you have severe side effects, is there anyone available to assist you?)
Download this helpful Information Sheet about speaking with your doctor regarding your treatment-related side effects.
